Embecta Shareholders Face August Deadline in Securities Class Action

The complaint alleges that Embecta leadership misled shareholders by touting the firm's pen needle business as resilient while concealing internal data that suggested the company’s performance targets were unreachable. These claims culminated on May 5, 2026, when the firm reported a 14% revenue decline—far exceeding previous projections of flat growth or minor losses. The disclosure wiped out more than half of the company's market value, as the share price plummeted from $9.25 to $3.90 in a single trading session.

The Gross Law Firm is currently organizing the class action to recover losses for those impacted by the disclosure. While shareholders do not need to serve as lead plaintiff to receive potential compensation, they must register their information to join the recovery efforts. The firm provides portfolio monitoring for registered participants throughout the litigation process at no initial cost to the investor.